Renub Research
www.renub.com
Hepatitis C (HCV) Market Forecast & Drugs
Pipeline Analysis to 2016
Publisher: Renub Research
Published: January, 2012
Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6
Billion in 2011 and is expected to be more than double of its current figure by 2015. This
robust growth will be driven primarily by the launch of novel premium-priced agents that will
increase the size of the drug-treated population, mainly as a result of the re-treatment of
prior non-responder patients.
Pegasys, Copegus and Pegintron were the only obtainable drugs in Hepatitis C drug market till
May 2011. Pegasys always had more revenue generation in any year compared to Pegintron
and is also expected to have higher revenue in future till 2016. However by the end of May
2011, the dynamics of the market has changed after the launch of Incivek and Victrelis.
Incivek sale has grown quickly and it garnered around US$ 400 Million by end of 3rd quarter
2011. It is expected that Incivek sales will be slightly less than US$ 4 Billion by 2015. On the
other hand Victrelis, which was approved a week before Incivek, is moving along a slower
adoption curve. Victrelis has lost its grip into the market and reaped only US$ 31 Million sales
by the end of 3rd quarter 2011.
In respect of these there are many other pipeline drugs, which are currently in clinical trial
Phase II or Phase III and expected to be launched by 2014. Pipeline drugs like Setrobuvir (ANA
598), RG-7128, TMC - 435 and Danoprevir are going to be the next game changers in the
Hepatitis C drug market. Renub Research report entitled “Hepatitis C (HCV) Market
Forecast & Drugs Pipeline Analysis to 2016” is an essential source of information and
analysis on the global HCV market. The report identifies the key trends shaping and driving
the global HCV market. The report also provides insight into the prevalent competitive
landscape, launched HCV drugs present and future performance, yet to be launched HCV
drugs forecast. Most importantly, the report provides valuable insight into the pipeline
products within the global Hepatitis C sector.
What We Have Achieved in this Report
Comprehensive situation analysis of the Global Hepatitis C drug market and its
dynamics.
Identifying all available drugs, pipeline drugs and their position in clinical trials and
quantifying their current and future market potential.
Providing a robust long range value forecast for all available drugs, pipeline drugs and
their position in clinical trial.
Providing an understanding of key drivers and restraints and their impact on current
and future market scenario.
Competitive Landscape
This section covers the key facts about the major companies that play an important role in
Hepatitis C drug market. The companies analyzed in this section are – Merck, Vertex
Pharmaceuticals, Roche, Pharmasset, Anadys Pharmaceuticals. All the companies have
been analyzed from two points of views.
1) Strength of the company in Hepatitis C drug market
2) Weakness of the company in Hepatitis C drug market.
Data Sources
This report is built using data and information sourced from proprietary databases, secondary
research and in-house analysis by Renub Research team of industry experts.
Secondary sources information and data has been collected from various printable and non-
printable sources like search engines, News websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 500 paid databases.
© Renub Research Page 3 of 15
About Us
Renub Research is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have long-term experience especially in
international Business-to-Business Researches, Surveys, Business and Consulting. Throughout
the years we have acquired expertise in most market sectors, including Information
Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services
(Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG,
Consumer Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.
For more information on us or to view any of our sample work you can
mail us at info@renub.com
© Renub Research Page 4 of 15
Published
By
Renub Research
A–116B, Sector–27
Noida – 201301
Phone: +91-120-421-9822, 254-5750 (India)
+1-678-302-0700 (USA)
Fax : +91-120-424-9780
Email: info@renub.com
www.renub.com
© Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
Renub Research, 2012
Edition 1.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers
© Renub Research Page 5 of 15
Table of Contents
1. Executive Summary
2. Global Hepatitis C Market & Forecast (2004 – 2015)
2.1 Merger & Acquisition in Hepatitis C Market (2006 - 2010)
3. Hepatitis C Drug Class Market & Future Trends
3.1 Modified Interferon Alphas Market & Forecast (2004 – 2014)
3.2 Nucleoside Analogues & IMPDH Inhibitors Market & Forecast (2004 – 2014)
3.3 HCV - Specific Antiviral Market & Forecast (2009 – 2014)
3.4 Non Interferon Alfa Immune Modulator Market (2009 – 2014)
4. Global – Top Hepatitis C Drugs Market & Forecast
4.1 Pegasys Sales & Forecast (2005 – 2016)
4.2 Pegintron Sales & Forecst (2009 – 2016)
4.3 Incivek (Telaprevir) Sales & Forecast (2011 – 2015)
4.4 Victrelis (Boceprevir) Sales & Forecast (2011 – 2015)
5. Pipeline Drug Forecast Analysis
5.1 Setrobuvir (ANA598) (Anadys Pharmaceuticals) Sales Forecast (2014 – 2018)
5.2 RG-7128 (Pharmasset) Sales Forecast (2014 – 2018)
5.3 TMC - 435 (Medivir & Tibotec) Sales Forecast (2014 – 2018)
5.4 Danoprevir (Roche) Sales Forecast (2014 – 2018)
6. Pipeline Drug Clinical Trial Statement
6.1 PSI-7977 (Pharmasset)
6.2 ABT-333(Abbott & Enanta Pharmaceuticals)
6.3 Vaniprevir (MK-7009)(Merck)
6.4 BI 201335 (Boehringer Ingelheim)
6.5 ABT-450 (Abbott Laboratories)
6.6 BMS-650032 (Bristol-Myers Squibb)
6.7 Setrobuvir (ANA 598) (Anadys Pharmaceuticals)
© Renub Research Page 6 of 15
6.8 Filibuvir (Pfizer)
6.9 VX-222 (Vertex)
6.10 GS-9190 (Gilead)
6.11 Danoprevir(Roche)
7. Key Drivers of Growth in Global Hepatitis C Drug Market
7.1 The Growing Crisis of HIV/HCV Co-infection
7.2 Rising Number of Illicit Drug Users (Drug Addict)
7.3 Rising Number of Injecting Drug Users
7.4 Unmet Medical Needs
8. Challenges in Hepatitis C Drug Market
8.1 Depression & Quality of Life
8.2 Initial Diagnosis & Decision to Treat
9. Competitive Landscape
9.1 Merck
9.1.1 Strength
9.1.2 Weakness
9.2 Vertex Pharmaceuticals
9.2.1 Strength
9.2.2 Weakness
9.3 Roche Holding Ltd
9.3.1 Strength
9.3.2 Weakness
9.4 Pharmasset, Inc. (Company acquired by GILEAD)
9.4.1 Strength
9.4.2 Weakness
9.5 Anadys Pharmaceuticals, Inc. (Company acquired by Roche)
9.5.1 Strength
9.5.2 Weakness
© Renub Research Page 7 of 15
List of Figures:
Figure 2-1: Global – Hepatitis C Market (Million US$), 2004 – 2011
Figure 2-2: Global – Forecast for Hepatitis C Market (Billion US$), 2012 – 2015
Figure 3-1: Global – Modified Interferon Alfa Market (Million US$), 2004 – 2011
Figure 3-2: Global – Forecast for Modified Interferon Alfa Market (Million US$), 2012 – 2014
Figure 3-3: Global – Nucleoside Analogues & IMPDH Inhibitors Market (Million US$), 2004 – 2011
Figure 3-4: Global – Forecast for Nucleoside Analogues & IMPDH Inhibitors Market (Million US$), 2012 –
2014
Figure 3-5: Global – HCV Specific Antiviral Market (Million US$), 2009 – 2011
Figure 3-6: Global – Forecast for HCV Specific Antiviral Market (Million US$), 2012 – 2014
Figure 3-7: Global – Non Interferon Alfa Immune Modulator Market (Million US$), 2009 – 2011
Figure 3-8: Global – Forecast for Non Interferon Alfa Immune Modulator Market (Million US$)
Figure 4-1: Global – Pegasys Drug Sales (Million US$), 2005 – 2011
Figure 4-2: Global – Forecast for Pegasys Drug Sales (Million US$), 2012 – 2016
Figure 4-3: Global – Pegintron Drug Sales (Million US$), 2009 – 2011
Figure 4-4: Global – Forecast for Pegintron Drug Sales (Million US$), 2012 – 2016
nd rd
Figure 4-5: Global – Incivek Drug Sales & Forecast (Million US$), 2 Qtr 2011, 3 Qtr 2011, 2011 – 2015
nd
Figure 4-6: Global – Victrelis (Boceprevir) Sales & Forecast (Million US$), 2 Qtr 2011, 3rd Qtr 2011,
2011 – 2015
Figure 5-1: Global – Forecast for Setrobuvir (ANA598) Drug Sales (Million US$), 2014 – 2018
Figure 5-2: Global – Forecast for RG - 7128 Market (Million US$), 2014 – 2018
Figure 5-3: Global – Forecast for TMC-435 Drug Market (Million US$), 2014 – 2018
Figure 5-4: Global – Forecast for Danoprevir Drug Sales (Million US$), 2014 – 2018
Figure 7-1: Global – Illicit Drug Users & Problem Drug Users (Million) 2001/02 – 2009/10
Figure 7-2: Global – Prevalence of Illicit Drug Use & Problem Drug Use (percent), 2001/02 – 2009/2010
Figure 7-3: Global – Opium Poppy Cultivation (Hectares), 1990, 1995, 2000, 2005 – 2010
Figure 7-4: Global – Coca Cultivation (Hectares), 1990, 1995, 2000, 2005 – 2010
© Renub Research Page 8 of 15
List of Tables:
Table 2-1: Global – Merger & Acquisition (Million US$) 2009 – 2011
Table 6-1: PSI – 7977 – Clinical Trials
Table 6-2: ABT – 333 – Clinical Trials
Table 6-3: Vaniprevir MK – 7009 – Clinical trials
Table 6-4: BI 201335 – Clinical Trials
Table 6-5: ABT-450 – Clinical Trials
Table 6-6: BMS – 650032 – Clinical Trials
Table 6-7: ANA 598 – Clinical Trials
Table 6-8: Filibuvir – Clinical Trials
Table 6-9: VX-222 – Clinical Trials
Table 6-10: GS-9190 – Clinical Trials
Table 6-11: Danoprevir – Clinical Trials
Table 7-1: Worldwide – HIV/HCV Co-infection Prevalence Rates in Selected Countries, 2008
Table 7-2: Worldwide – HCV Prevalence among People Who Inject Drugs and Prison Populations in
Selected Countries, 2008
Table 7-3: Region & Sub-region – Illicit Drug Users of Cannabis & Opioid Aged 15 – 64, (Number), 2009
Table 7-4: Region & Sub-region – Illicit Drug Users of Opiate & Cocaine Aged 15 – 64 (Number), 2009
Table 7-5: Region & Sub-region – Illicit Drug Users of Amphetamines & Ecstasy Aged 15 – 64 (Number),
2009
Table 7-6: Global – Hepatitis C Prevalence among Injecting Drug Users (Percent)
Table 8-1: Ireland – Predictors of Depressive Disorder Diagnosed Using the SCID – CV
Table 8-2: Ireland – Illness Related Predictors of Depressive Disorder Diagnosed using the SCID – CV
Table 9-1: Merck – Key Financials (Million US$) 2008 – 2010
Table 9-2: Vertex – Key Financials (Million US$), 2008 – 2010
Table 9-3: Roche – Key Financials (Million US$) 2008 – 2010
Table 9-4: Pharmasset – Key Financials (Million US$) 2008 – 2010
Table 9-5: Anadys – Key Financials (Million US$) 2007 – 2009
© Renub Research Page 9 of 15
Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com
Format
Report Title: Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
Single User Hard Copy CD – Rom Global Site License
(Email from Publisher) (Mail Delivery) (Mail Delivery) (Multiple User License)
US$ 975 US$ 1,075 US$ 1,075 US$ 1,500
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/reports/showdetails.aspx?id=55
2) Order by Wire Transfer:
http://www.renub.com/reports/wiretransfer.aspx?id=55&pid=1198
To pay by Wire Transfer, please, fill in your contact details in the form below:
© Renub Research Page 10 of 15
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:
© Renub Research Page 11 of 15
3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
A -116B
Sector -27
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch
© Renub Research Page 12 of 15
Related Reports
Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast
Genetic Testing Market and Forecast - Global Analysis 2010 – 2015
USA Cardiovascular Devices Market Trends and Forecast (2010 – 2015)
Global Osteoporosis Market & Drugs Analysis 2010 – 2015
Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)
Global Molecular Diagnostics Market & Future Forecast 2010 - 2014
Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs
Analysis
Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
Global In Vitro Diagnostics (IVD) Market Trends and Future Forecast (2009 – 2014)
Glucose Monitoring Devices Market Worldwide (2010 – 2014)
Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin,
DPP-IV, GLP-1
Global Molecular Diagnostics Market: Opportunities & Future Forecast
Insulin Delivery Devices Market Analysis and Future Forecast
World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments
© Renub Research Page 13 of 15
Our Partial List of Clients
Redbus Bain
Becton Dickinson WAKE Technology Services, Inc.
Pfizer PSS World Medical
Intercell Relypsa
Sanofi Pasteur C&K components
Stanford Burgess Konkuk University
Pequot Capital Resonetics
DMI Samsung
Transgene S.A. SEKISUI MEDICAL CO. LTD.
ixia communications Plentyoffish Media INC
Toyota Tsusho Amercia Inc. Arthur D Little Gmbh
National Health Research Institutes Morgan Stanley
Abbott Diabetes Care Takeda Pharmaceutical Corporation
Corning Incorporated - Life Sciences Hokkai School of Commerce
L.E.K. Consulting GmbH Ministry of Manpower Singapore
Syntiron GenOmind, LLC.
MediVas LLC Goldman Sachs & Co
Credit Suisse NTT Advanced Technology
Dune Medical Tokyo Womens Medical University
QIAGEN The Chemo-Sero-Therapeutic Research
Inje University Trade Council of Iceland
Mapp Biopharmaceutical Jpmorgan, Ets Trading
Institute for Information Industry GE Healthcare IT
NorDiag ASA ixia communications
© Renub Research Page 14 of 15
Rep e Inv Medicas SA de
Innogenetics
Disclaimer
This research report is published by Renub Research. All rights reserved. Reproduction or
redistribution of this research report in any form for any business purpose is expressly
prohibited without written permission of www.renub.com and any payments of a specified
fee. Requests to republish any material may be sent to us at info@renub.com.
Most of the information available in this report is within the public domain. The submitting
authors or other copyright holders retain rights for reproduction or redistribution. All persons
reproducing or redistributing this information are expected to adhere to the terms and
constraints invoked by the copyright holder. Such protected material, however, may be used
under the terms of "fair use” as defined in the copyright laws, which generally permit use for
non-commercial educational purposes such as teaching, research, criticism, and news
reporting.
With respect to documents available, neither the company nor any of its employees makes
any warranty, express or implied, including the warranties of merchantability and fitness for
a particular purpose, or assumes any legal liability or responsibility for the accuracy,
completeness, or usefulness of any information, apparatus, product, or process disclosed, or
represents that its use would not infringe privately owned rights.
© Renub Research Page 15 of 15